{"symbol": "JNJ", "publishedDate": "2025-01-08 08:00:00", "publisher": "PRNewsWire", "title": "Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease", "image": "https://images.financialmodelingprep.com/news/johnson-johnsons-posdinemab-and-tau-active-immunotherapy-receive-us-20250108.jpg", "site": "prnewswire.com", "text": "Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's commitment to Alzheimer's disease development and the potential of its precision approach TITUSVILLE, N.J. , Jan. 8, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease (AD) in the Phase 2b \"AuTonomy\" study.", "url": "https://www.prnewswire.com/news-releases/johnson--johnsons-posdinemab-and-tau-active-immunotherapy-receive-us-fda-fast-track-designations-for-the-treatment-of-alzheimers-disease-302345029.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-08T08:00:00-05:00", "date_et": "2025-01-08"}
{"symbol": "JNJ", "publishedDate": "2025-01-08 12:13:05", "publisher": "Seeking Alpha", "title": "Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer", "image": "https://images.financialmodelingprep.com/news/dividend-roundup-why-i-prefer-johnson-johnson-over-pfizer-20250108.jpg", "site": "seekingalpha.com", "text": "The latest dividend declarations, combined with stock price movements, have pushed PFE's yield to be almost twice as JNJ's. But I want to caution you to look beyond yield (and P/E too) and examine other aspects, especially those often overlooked by dividend investors. JNJ offers better growth, a stronger track record, and also a safer payout.", "url": "https://seekingalpha.com/article/4748338-dividend-roundup-why-i-prefer-johnson-and-johnson-over-pfizer", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-08T12:13:05-05:00", "date_et": "2025-01-08"}
{"symbol": "JNJ", "publishedDate": "2025-01-08 13:44:47", "publisher": "Investors Business Daily", "title": "J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product", "image": "https://images.financialmodelingprep.com/news/jj-falls-while-boston-scientific-medtronic-pop-after-strokes-20250108.jpg", "site": "investors.com", "text": "Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system. The post J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product appeared first on Investor's Business Daily.", "url": "https://www.investors.com/news/technology/johnson-johnson-stock-pulsed-field-ablation/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-08T13:44:47-05:00", "date_et": "2025-01-08"}
{"symbol": "JNJ", "publishedDate": "2025-01-08 14:24:54", "publisher": "Reuters", "title": "J&J pauses rollout of heart device in the US to investigate stroke risk", "image": "https://images.financialmodelingprep.com/news/jj-pauses-rollout-of-heart-device-in-the-us-20250108.jpg", "site": "reuters.com", "text": "Johnson & Johnson said on Wednesday that it has temporarily paused the rollout of its Varipulse heart device in the United States, citing an abundance of caution as the company investigates four reported stroke events.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jj-pauses-rollout-heart-device-us-investigate-stroke-risk-2025-01-08/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-08T14:24:54-05:00", "date_et": "2025-01-08"}
{"symbol": "JNJ", "publishedDate": "2025-01-09 08:04:00", "publisher": "PRNewsWire", "title": "Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis", "image": "https://images.financialmodelingprep.com/news/nipocalimab-granted-us-fda-priority-review-for-the-treatment-20250109.jpg", "site": "prnewswire.com", "text": "Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive adult patients: anti-AChR, anti-MuSK, anti-LRP4 SPRING HOUSE, Pa. , Jan. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study.", "url": "https://www.prnewswire.com/news-releases/nipocalimab-granted-us-fda-priority-review-for-the-treatment-of-generalized-myasthenia-gravis-302346976.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-09T08:04:00-05:00", "date_et": "2025-01-09"}
{"symbol": "JNJ", "publishedDate": "2025-01-09 09:35:20", "publisher": "Zacks Investment Research", "title": "J&J Pauses Sales of Atrial Fibrillation Device, Stock Down", "image": "https://images.financialmodelingprep.com/news/jj-pauses-sales-of-atrial-fibrillation-device-stock-down-20250109.jpg", "site": "zacks.com", "text": "J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.", "url": "https://www.zacks.com/stock/news/2394247/j-j-pauses-sales-of-atrial-fibrillation-device-stock-down?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2394247", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-09T09:35:20-05:00", "date_et": "2025-01-09"}
{"symbol": "JNJ", "publishedDate": "2025-01-09 10:01:43", "publisher": "Zacks Investment Research", "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar", "image": "https://images.financialmodelingprep.com/news/these-2-medical-stocks-could-beat-earnings-why-they-20250109.jpg", "site": "zacks.com", "text": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.", "url": "https://www.zacks.com/stock/news/2394287/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_earnings_esp-2394287", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-09T10:01:43-05:00", "date_et": "2025-01-09"}
{"symbol": "JNJ", "publishedDate": "2025-01-10 04:51:00", "publisher": "The Motley Fool", "title": "2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid", "image": "https://images.financialmodelingprep.com/news/2-dow-stocks-to-buy-hand-over-fist-in-20250110.jpg", "site": "fool.com", "text": "The second year of Wall Street's bull market rally didn't disappoint, with all three major stock indexes hitting fresh all-time highs. This includes the ageless Dow Jones Industrial Average (^DJI 0.25%), which reached a record-closing high of more than 45,000 on Dec. 4.", "url": "https://www.fool.com/investing/2025/01/10/2-dow-stocks-to-buy-hand-over-fist-2025-1-to-avoid/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-10T04:51:00-05:00", "date_et": "2025-01-10"}
{"symbol": "JNJ", "publishedDate": "2025-01-10 09:00:00", "publisher": "The Motley Fool", "title": "4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025", "image": "https://images.financialmodelingprep.com/news/4-top-dividend-growth-stocks-to-build-your-portfolio-20250110.jpg", "site": "fool.com", "text": "You will want to build your portfolio the right way if you're going to make money with stocks over the long haul. You wouldn't build your house on a shaky foundation, would you?", "url": "https://www.fool.com/investing/2025/01/10/4-dividend-growth-stocks-to-build-your-portfolio/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-10T09:00:00-05:00", "date_et": "2025-01-10"}
{"symbol": "JNJ", "publishedDate": "2025-01-10 09:25:30", "publisher": "Zacks Investment Research", "title": "FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab", "image": "https://images.financialmodelingprep.com/news/fda-accepts-jjs-filing-for-autoimmune-disease-drug-nipocalimab-20250110.jpg", "site": "zacks.com", "text": "JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.", "url": "https://www.zacks.com/stock/news/2394899/fda-accepts-j-j-s-filing-for-autoimmune-disease-drug-nipocalimab?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2394899", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-10T09:25:30-05:00", "date_et": "2025-01-10"}
{"symbol": "JNJ", "publishedDate": "2025-01-10 11:19:58", "publisher": "Forbes", "title": "What To Expect From JNJ Stock In 2025?", "image": "https://images.financialmodelingprep.com/news/what-to-expect-from-jnj-stock-in-2025-20250110.jpg", "site": "forbes.com", "text": "Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly stock (up 31%) and AbbVie stock (up 15%), Johnson & Johnson's stock performance has been muted.", "url": "https://www.forbes.com/sites/greatspeculations/2025/01/10/what-to-expect-from-jnj-stock-in-2025/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-10T11:19:58-05:00", "date_et": "2025-01-10"}
{"symbol": "JNJ", "publishedDate": "2025-01-10 13:15:00", "publisher": "Accesswire", "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ", "image": "https://images.financialmodelingprep.com/news/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson-20250110.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson. (\"J&J\" or the \"Company\") (NYSE:JNJ).", "url": "https://www.accesswire.com/966856/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson-johnson--jnj", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-10T13:15:00-05:00", "date_et": "2025-01-10"}
{"symbol": "JNJ", "publishedDate": "2025-01-10 13:15:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Investors to Reach Out", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-initiates-an-investigation-into-allegations-20250110.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accesswire.com/966865/bronstein-gewirtz-grossman-llc-initiates-an-investigation-into-allegations-against-johnson-johnson-jnj-and-encourages-investors-to-reach-out", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-10T13:15:00-05:00", "date_et": "2025-01-10"}
{"symbol": "JNJ", "publishedDate": "2025-01-10 16:15:00", "publisher": "Accesswire", "title": "JNJ ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Johnson & Johnson investment", "image": "https://images.financialmodelingprep.com/news/jnj-active-investigation-contact-levi-korsinsky-if-you-lost-20250110.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accesswire.com/966978/jnj-active-investigation-contact-levi-korsinsky-if-you-lost-money-on-your-johnson-johnson-investment", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-10T16:15:00-05:00", "date_et": "2025-01-10"}
{"symbol": "JNJ", "publishedDate": "2025-01-11 06:36:59", "publisher": "Seeking Alpha", "title": "Johnson & Johnson Could Serve As High-Yield Bond Alternative", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-could-serve-as-highyield-bond-alternative-20250111.jpg", "site": "seekingalpha.com", "text": "Johnson & Johnson remains a \"Buy\" for its stability and consistent dividends, despite short-term price fluctuations and modest growth expectations. Q3 2024 results showed a 5.2% sales increase but a significant decline in earnings, highlighting mixed performance across segments. The company's strong economic moat, stable margins, and high return on invested capital support its long-term investment appeal.", "url": "https://seekingalpha.com/article/4748883-johnson-and-johnson-could-serve-as-high-yield-bond-alternative", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-11T06:36:59-05:00", "date_et": "2025-01-11"}
{"symbol": "JNJ", "publishedDate": "2025-01-12 10:00:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Investors to Inquire about Securities Investigation", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-encourages-johnson-johnson-jnj-investors-20250112.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accesswire.com/966866/bronstein-gewirtz-grossman-llc-encourages-johnson-johnson-jnj-investors-to-inquire-about-securities-investigation", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-12T10:00:00-05:00", "date_et": "2025-01-12"}
{"symbol": "JNJ", "publishedDate": "2025-01-12 11:00:00", "publisher": "Accesswire", "title": "Levi & Korsinsky Investigates Possible Securities Fraud Violations by Johnson & Johnson (JNJ)", "image": "https://images.financialmodelingprep.com/news/levi-korsinsky-investigates-possible-securities-fraud-violations-by-johnson-20250112.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accesswire.com/967303/levi-korsinsky-investigates-possible-securities-fraud-violations-by-johnson-johnson-jnj", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-12T11:00:00-05:00", "date_et": "2025-01-12"}
{"symbol": "JNJ", "publishedDate": "2025-01-12 16:35:42", "publisher": "Reuters", "title": "J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports", "image": "https://images.financialmodelingprep.com/news/jj-explores-bid-for-intracellular-therapies-bloomberg-news-reports-20250112.jpg", "site": "reuters.com", "text": "Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies Inc , a biopharmaceutical company, Bloomberg News reported on Sunday citing people familiar with the matter.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jj-explores-bid-intra-cellular-therapies-bloomberg-news-reports-2025-01-12/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-12T16:35:42-05:00", "date_et": "2025-01-12"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 04:16:04", "publisher": "Proactive Investors", "title": "Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-eyes-10bn-acquisition-of-intracellular-therapies-20250113.jpg", "site": "proactiveinvestors.co.uk", "text": "Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the deal would mark the largest biotech acquisition since Pfizer's $43bn purchase of Seagen in 2023.", "url": "https://www.proactiveinvestors.co.uk/companies/news/1064140", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T04:16:04-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 05:41:00", "publisher": "Barrons", "title": "This Stock Is Soaring Amid J&J Takeover Report", "image": "https://images.financialmodelingprep.com/news/this-stock-is-soaring-amid-jj-takeover-report-20250113.jpg", "site": "barrons.com", "text": "A deal could be reached for the biotech company this week, according to a media report.", "url": "https://www.barrons.com/articles/j-and-j-takeover-intra-cellular-johnson-and-johnson-01985342", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T05:41:00-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 06:09:00", "publisher": "The Motley Fool", "title": "2 Beaten-Down Dividend Stocks to Buy in 2025", "image": "https://images.financialmodelingprep.com/news/2-beatendown-dividend-stocks-to-buy-in-2025-20250113.jpg", "site": "fool.com", "text": "Dividend stocks are great for various reasons, and it's even better to invest in them while they are going through a rough patch, provided there are good reasons to believe they will recover. This description fits several dividend stocks on the market, among which are CVS Health (CVS 4.35%) and Johnson & Johnson (JNJ -0.15%).", "url": "https://www.fool.com/investing/2025/01/13/2-beaten-down-dividend-stocks-to-buy-in-2025/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T06:09:00-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 06:30:00", "publisher": "Business Wire", "title": "Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intracellular-therapies-inc-20250113.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value.", "url": "https://www.businesswire.com/news/home/20250113969534/en/Johnson-Johnson-Strengthens-Neuroscience-Leadership-with-Acquisition-of-Intra-Cellular-Therapies-Inc./", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T06:30:00-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 06:38:07", "publisher": "Reuters", "title": "J&J to buy Intra-Cellular Therapies for $14.6 billion", "image": "https://images.financialmodelingprep.com/news/jj-to-buy-intracellular-therapies-for-146-billion-20250113.jpg", "site": "reuters.com", "text": "Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.", "url": "https://www.reuters.com/markets/deals/jj-buy-intra-cellular-therapies-146-billion-2025-01-13/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T06:38:07-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 07:13:00", "publisher": "Market Watch", "title": "Johnson & Johnson makes $15 billion bet on mental-health drugs", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-makes-15-billion-bet-on-mentalhealth-drugs-20250113.jpg", "site": "marketwatch.com", "text": "Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts' expectations through 2029.", "url": "https://www.marketwatch.com/story/johnson-johnson-makes-15-billion-bet-on-mental-health-drugs-967e0b41", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T07:13:00-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 09:58:32", "publisher": "The Fly", "title": "Intra-Cellular just downgraded at Morgan Stanley, here's why", "image": "https://images.financialmodelingprep.com/news/intracellular-just-downgraded-at-morgan-stanley-heres-why-20250113.jpg", "site": "https://thefly.com", "text": "Intra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%)", "url": "https://thefly.com/permalinks/entry.php/id4050714/ITCI;JNJ-IntraCellular-just-downgraded-at-Morgan-Stanley-heres-why", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T09:58:32-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 10:00:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Stockholders to Learn More About the Investigation", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-johnson-20250113.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accesswire.com/966867/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-johnson-johnson-jnj-and-encourages-stockholders-to-learn-more-about-the-investigation", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T10:00:00-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 10:03:27", "publisher": "Benzinga", "title": "Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal", "image": "https://images.financialmodelingprep.com/news/like-bristolmyers-squibb-and-abbvie-johnson-johnson-seeks-to-20250113.jpg", "site": "benzinga.com", "text": "On Monday, Johnson & Johnson JNJ agreed to acquire Intra-Cellular Therapies Inc. ITCI for $132.00 per share in cash for a total equity value of approximately $14.6 billion.", "url": "https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T10:03:27-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 10:30:00", "publisher": "Accesswire", "title": "Lost Money on Johnson & Johnson(JNJ)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky", "image": "https://images.financialmodelingprep.com/news/lost-money-on-johnson-johnsonjnj-you-may-have-been-20250113.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accesswire.com/967653/lost-money-on-johnson-johnsonjnj-you-may-have-been-affected-by-fraud--contact-levi-korsinsky", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T10:30:00-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 12:07:32", "publisher": "Reuters", "title": "Drugmakers rush to sign deals on first day of industry conference", "image": "https://images.financialmodelingprep.com/news/drugmakers-rush-to-sign-deals-on-first-day-of-20250113.jpg", "site": "reuters.com", "text": "Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-rush-sign-deals-first-day-industry-conference-2025-01-13/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T12:07:32-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 13:06:00", "publisher": "Business Wire", "title": "Dean Omar Branham Shirley's Partners Named to List of 500 Leading Lawyers in America", "image": "https://images.financialmodelingprep.com/news/dean-omar-branham-shirleys-partners-named-to-list-of-20250113.jpg", "site": "businesswire.com", "text": "DALLAS--(BUSINESS WIRE)--Dean Omar Branham Shirley, a plaintiff firm known for aggressively advocating for the rights of consumers, announced that name partners Jessica Dean and Trey Branham have been named among the nation's most talented and experienced attorneys in Lawdragon's 500 Leading Lawyers in America for 2025. Lawdragon describes this guide as a celebration of “lawyering and those whose art is its craft.” “Thank you to those who considered us for this honor,” stated Mr. Branham. “The.", "url": "https://www.businesswire.com/news/home/20250113737393/en/Dean-Omar-Branham-Shirley%E2%80%99s-Partners-Named-to-List-of-500-Leading-Lawyers-in-America/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T13:06:00-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 14:23:32", "publisher": "The Fly", "title": "BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal", "image": "https://images.financialmodelingprep.com/news/bofa-moves-to-no-rating-on-intracellular-after-johnson-20250113.jpg", "site": "https://thefly.com", "text": "Intra-Cellular +32.49 (+34.25%) Johnson & Johnson +2.22 (+1.56%)", "url": "https://thefly.com/permalinks/entry.php/id4050861/ITCI;JNJ-BofA-moves-to-No-Rating-on-IntraCellular-after-Johnson-amp-Johnson-deal", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T14:23:32-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 16:27:12", "publisher": "Seeking Alpha", "title": "Johnson & Johnson (JNJ) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-43rd-annual-jp-morgan-healthcare-conference-20250113.jpg", "site": "seekingalpha.com", "text": "Johnson & Johnson (NYSE:JNJ ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 12:00 PM ET Company Participants Joaquin Duato - Chairman & CEO Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody.", "url": "https://seekingalpha.com/article/4749211-johnson-and-johnson-jnj-43rd-annual-j-p-morgan-healthcare-conference-transcript", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T16:27:12-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 18:10:02", "publisher": "Seeking Alpha", "title": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025", "image": "https://images.financialmodelingprep.com/news/top-5-cancer-pharma-stocks-with-strong-riskreward-in-20250113.jpg", "site": "seekingalpha.com", "text": "This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.", "url": "https://seekingalpha.com/article/4749221-top-5-cancer-pharma-stocks-with-strong-riskreward-in-2025", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T18:10:02-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 18:38:00", "publisher": "Business Wire", "title": "INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI", "image": "https://images.financialmodelingprep.com/news/intracellular-therapies-investor-alert-by-the-former-attorney-general-20250113.jpg", "site": "businesswire.com", "text": "NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t.", "url": "https://www.businesswire.com/news/home/20250113585941/en/INTRA-CELLULAR-THERAPIES-INVESTOR-ALERT-by-the-Former-Attorney-General-of-Louisiana-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Intra-Cellular-Therapies-Inc.---ITCI/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T18:38:00-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-13 20:00:21", "publisher": "Yahoo Finance", "title": "Healthcare sector poised for rebound in 2025", "image": "https://images.financialmodelingprep.com/news/healthcare-sector-poised-for-rebound-in-2025-20250113.jpg", "site": "youtube.com", "text": "The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).", "url": "https://www.youtube.com/watch?v=bEA-eeFGQ0Y", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-13T20:00:21-05:00", "date_et": "2025-01-13"}
{"symbol": "JNJ", "publishedDate": "2025-01-14 03:58:02", "publisher": "Proactive Investors", "title": "Trellus Health shares jump 180% on Johnson & Johnson collaboration", "image": "https://images.financialmodelingprep.com/news/trellus-health-shares-jump-180-on-johnson-johnson-collaboration-20250114.jpg", "site": "proactiveinvestors.co.uk", "text": "Shares in Trellus Health PLC (AIM:TRLS) soared 180% after the company announced a collaboration with Johnson & Johnson (NYSE:JNJ) Health Care Systems Inc. The partnership will pilot Trellus Health's digital platform, Trellus Elevate, in the US to support patients with moderate to severe inflammatory bowel disease (IBD).", "url": "https://www.proactiveinvestors.co.uk/companies/news/1064223", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-14T03:58:02-05:00", "date_et": "2025-01-14"}
{"symbol": "JNJ", "publishedDate": "2025-01-14 06:00:00", "publisher": "Seeking Alpha", "title": "7 Blue Chip Dividend Stocks I Used To Build My First $100K Portfolio", "image": "https://images.financialmodelingprep.com/news/7-blue-chip-dividend-stocks-i-used-to-build-20250114.jpg", "site": "seekingalpha.com", "text": "Building good financial habits and avoiding debt traps is the hardest part of accumulating your first $100K. Invest in companies with growing earnings, consistent dividends, low debt, and an established presence for long-term stability and market resilience. My 7-stock portfolio outperformed the S&P 500, tripling value and dividend income over 10 years with lower volatility.", "url": "https://seekingalpha.com/article/4749172-7-blue-chip-dividend-stocks-i-used-to-build-my-first-100k-portfolio", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-14T06:00:00-05:00", "date_et": "2025-01-14"}
{"symbol": "JNJ", "publishedDate": "2025-01-14 10:00:00", "publisher": "Accesswire", "title": "Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-investigation-bronstein-gewirtz-grossman-llc-encourages-20250114.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accesswire.com/966868/johnson-johnson-jnj-investigation-bronstein-gewirtz-grossman-llc-encourages-stockholders-to-contact-the-firm-to-learn-more-about-the-investigation", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-14T10:00:00-05:00", "date_et": "2025-01-14"}
{"symbol": "JNJ", "publishedDate": "2025-01-14 10:01:10", "publisher": "Zacks Investment Research", "title": "Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?", "image": "https://images.financialmodelingprep.com/news/is-trending-stock-johnson-johnson-jnj-a-buy-now-20250114.jpg", "site": "zacks.com", "text": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "url": "https://www.zacks.com/stock/news/2396467/is-trending-stock-johnson-johnson-jnj-a-buy-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2396467", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-14T10:01:10-05:00", "date_et": "2025-01-14"}
{"symbol": "JNJ", "publishedDate": "2025-01-14 10:30:00", "publisher": "Accesswire", "title": "JNJ ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Johnson & Johnson Shareholders Who Lost Money", "image": "https://images.financialmodelingprep.com/news/jnj-alert-levi-korsinsky-has-commenced-an-investigation-on-20250114.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accesswire.com/968362/jnj-alert-levi-korsinsky-has-commenced-an-investigation-on-behalf-of-johnson-johnson-shareholders-who-lost-money", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-14T10:30:00-05:00", "date_et": "2025-01-14"}
{"symbol": "JNJ", "publishedDate": "2025-01-14 16:00:28", "publisher": "Zacks Investment Research", "title": "JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference", "image": "https://images.financialmodelingprep.com/news/jnj-gsk-lly-announce-ma-deals-at-jp-morgan-20250114.jpg", "site": "zacks.com", "text": "J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.", "url": "https://www.zacks.com/stock/news/2396844/jnj-gsk-lly-announce-m-a-deals-at-jp-morgan-conference?cid=CS-STOCKNEWSAPI-FT-analyst_blog|industry_focus-2396844", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-14T16:00:28-05:00", "date_et": "2025-01-14"}
{"symbol": "JNJ", "publishedDate": "2025-01-15 05:10:00", "publisher": "The Motley Fool", "title": "Got $200? 2 Dividend Stocks to Buy and Hold Forever", "image": "https://images.financialmodelingprep.com/news/got-200-2-dividend-stocks-to-buy-and-hold-20250115.jpg", "site": "fool.com", "text": "Medicine is the cornerstone of healthcare. That remains true today, with a global pharmaceutical industry valued at $1.4 trillion and expected to grow at 6.1% annually through 2030.", "url": "https://www.fool.com/investing/2025/01/15/got-200-2-dividend-stocks-to-buy-and-hold-forever/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-15T05:10:00-05:00", "date_et": "2025-01-15"}
{"symbol": "JNJ", "publishedDate": "2025-01-15 08:00:00", "publisher": "PRNewsWire", "title": "New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer", "image": "https://images.financialmodelingprep.com/news/new-drug-application-initiated-with-us-fda-for-tar200-20250115.jpg", "site": "prnewswire.com", "text": "Application accepted for U.S. FDA Real-Time Oncology Review (RTOR) based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1 RARITAN, N.J. , Jan. 15, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration (FDA) for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.", "url": "https://www.prnewswire.com/news-releases/new-drug-application-initiated-with-us-fda-for-tar-200-the-first-and-only-intravesical-drug-releasing-system-for-patients-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-302351745.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-15T08:00:00-05:00", "date_et": "2025-01-15"}
{"symbol": "JNJ", "publishedDate": "2025-01-15 08:15:00", "publisher": "Accesswire", "title": "JNJ ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Johnson & Johnson Shareholders Who Lost Money", "image": "https://images.financialmodelingprep.com/news/jnj-alert-levi-korsinsky-has-commenced-an-investigation-on-20250115.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accesswire.com/968917/jnj-alert--levi-korsinsky-has-commenced-an-investigation-on-behalf-of-johnson-johnson-shareholders-who-lost-money", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-15T08:15:00-05:00", "date_et": "2025-01-15"}
{"symbol": "JNJ", "publishedDate": "2025-01-15 10:00:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Stockholders to Connect", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-is-investigating-johnson-johnson-jnj-20250115.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accesswire.com/966869/bronstein-gewirtz-grossman-llc-is-investigating-johnson-johnson-jnj-and-encourages-stockholders-to-connect", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-15T10:00:00-05:00", "date_et": "2025-01-15"}
{"symbol": "JNJ", "publishedDate": "2025-01-15 10:30:00", "publisher": "Accesswire", "title": "JNJ ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Johnson & Johnson", "image": "https://images.financialmodelingprep.com/news/jnj-alert-levi-korsinsky-reminds-investors-of-an-investigation-20250115.jpg", "site": "accesswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accesswire.com/968963/jnj-alert-levi-korsinsky-reminds-investors-of-an-investigation-involving-possible-securities-fraud-violations-by-johnson-johnson", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-15T10:30:00-05:00", "date_et": "2025-01-15"}
{"symbol": "JNJ", "publishedDate": "2025-01-15 12:39:57", "publisher": "Seeking Alpha", "title": "Buy 3 'Safer' Dividend Kings Of 25 From 53 For January", "image": "https://images.financialmodelingprep.com/news/buy-3-safer-dividend-kings-of-25-from-53for-20250115.jpg", "site": "seekingalpha.com", "text": "“A Dividend King [is] a stock with 50 or more consecutive years of dividend increases.”—suredividend.com. 53 Divided Kings, screened as of January 10, 2025, represented all eleven Morningstar Sectors. Broker-estimated top-ten net-gains ranged 22.84%-62.53% topped-by SJW & SCL. By yield, MO topped all the Kings. Top-ten Yields from KVUE, SWK, UBSI, FTS, FRT, BKH, NWN, CDUAF, UVV, & MO, averaged 5.04%.", "url": "https://seekingalpha.com/article/4749682-buy-3-safer-dividend-kings-of-25-from-53for-january", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-15T12:39:57-05:00", "date_et": "2025-01-15"}
{"symbol": "JNJ", "publishedDate": "2025-01-16 06:14:00", "publisher": "GlobeNewsWire", "title": "U.S. Cancer Biopsy Market and Competition Analysis, 2025-2030, Featuring Key Players - BD, IZI Medical Products, Johnson & Johnson Services, Argon Medical Devices, Spectra Medical Devices & More", "image": "https://images.financialmodelingprep.com/news/us-cancer-biopsy-market-and-competition-analysis-20252030-featuring-20250116.jpg", "site": "globenewswire.com", "text": "Blood-Based Multi-Cancer Early Detection (MCED) Technologies Poised to Offer Lucrative Opportunities Blood-Based Multi-Cancer Early Detection (MCED) Technologies Poised to Offer Lucrative Opportunities", "url": "https://www.globenewswire.com/news-release/2025/01/16/3010629/28124/en/U-S-Cancer-Biopsy-Market-and-Competition-Analysis-2025-2030-Featuring-Key-Players-BD-IZI-Medical-Products-Johnson-Johnson-Services-Argon-Medical-Devices-Spectra-Medical-Devices-Mor.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-16T06:14:00-05:00", "date_et": "2025-01-16"}
{"symbol": "JNJ", "publishedDate": "2025-01-16 07:30:00", "publisher": "Seeking Alpha", "title": "The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems", "image": "https://images.financialmodelingprep.com/news/the-nearperfect-dividend-portfolio-with-10-sleepwellatnight-gems-20250116.jpg", "site": "seekingalpha.com", "text": "In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable dividend stocks thrive despite volatility, offering steady income and solid growth in uncertain times. Building a balanced portfolio of 10 carefully selected SWAN stocks ensures consistent returns. This strategy offers peace of mind, regardless of market fluctuations.", "url": "https://seekingalpha.com/article/4749762-the-near-perfect-dividend-portfolio-with-10-sleep-well-at-night-gems", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-16T07:30:00-05:00", "date_et": "2025-01-16"}
{"symbol": "JNJ", "publishedDate": "2025-01-16 08:46:14", "publisher": "Zacks Investment Research", "title": "J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug", "image": "https://images.financialmodelingprep.com/news/jj-seeks-fda-nod-for-nonmuscle-invasive-bladder-cancer-20250116.jpg", "site": "zacks.com", "text": "JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer patients.", "url": "https://www.zacks.com/stock/news/2397994/j-j-seeks-fda-nod-for-non-muscle-invasive-bladder-cancer-drug?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2397994", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-16T08:46:14-05:00", "date_et": "2025-01-16"}
{"symbol": "JNJ", "publishedDate": "2025-01-16 08:50:07", "publisher": "24/7 Wall Street", "title": "Dogs of the Dow: Can These 3 Laggards Turn a Corner in 2025?", "image": "https://images.financialmodelingprep.com/news/dogs-of-the-dow-can-these-3-laggards-turn-20250116.jpg", "site": "247wallst.com", "text": "The Dogs of the Dow strategy doesn't always work. Often, it can lead investors to a laggard poised to lag behind for yet another year.", "url": "https://247wallst.com/investing/2025/01/16/dogs-of-the-dow-can-these-3-laggards-turn-a-corner-in-2025/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-16T08:50:07-05:00", "date_et": "2025-01-16"}
{"symbol": "JNJ", "publishedDate": "2025-01-16 10:00:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Investors to Connect", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-is-investigating-johnson-johnson-jnj-20250116.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-johnson-and-johnson-jnj-and-encourages-investors-to-connect-966870", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-16T10:00:00-05:00", "date_et": "2025-01-16"}
{"symbol": "JNJ", "publishedDate": "2025-01-16 10:20:42", "publisher": "Zacks Investment Research", "title": "Insights Into Johnson & Johnson (JNJ) Q4: Wall Street Projections for Key Metrics", "image": "https://images.financialmodelingprep.com/news/insights-into-johnson-johnson-jnj-q4-wall-street-projections-20250116.jpg", "site": "zacks.com", "text": "Beyond analysts' top -and-bottom-line estimates for Johnson & Johnson (JNJ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.", "url": "https://www.zacks.com/stock/news/2398140/insights-into-johnson-johnson-jnj-q4-wall-street-projections-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2398140", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-16T10:20:42-05:00", "date_et": "2025-01-16"}
{"symbol": "JNJ", "publishedDate": "2025-01-16 11:29:04", "publisher": "Seeking Alpha", "title": "Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-q4-earnings-may-not-prompt-sustained-directional-20250116.jpg", "site": "seekingalpha.com", "text": "Johnson & Johnson has underperformed its lerge-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Even though JNJ has displayed an improvingtrack record of beating consensus EPS,the Q4 earnings event, due to be held on the 22nd of Jan, may not significantly boost the stock. Question marks over the rising debt driven by M&A, the uncertainty surrounding the talcum powder lawsuits, slowing dividend growth and potentially lower FY25 EPS guidance may weigh heavily.", "url": "https://seekingalpha.com/article/4749953-johnson-and-johnson-q4-earnings-may-not-prompt-sustained-directional-moves", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-16T11:29:04-05:00", "date_et": "2025-01-16"}
{"symbol": "JNJ", "publishedDate": "2025-01-17 08:00:31", "publisher": "MarketBeat", "title": "Is Johnson & Johnson Stock Set to Reward Long-Term Holders?", "image": "https://images.financialmodelingprep.com/news/is-johnson-johnson-stock-set-to-reward-longterm-holders-20250117.jpg", "site": "marketbeat.com", "text": "In fact, Johnson & Johnson is one of the companies that is part of the exclusive dividend kings. The company has been increasing its dividend for 62 consecutive years, and the company's rock-solid balance sheet backs that dividend.", "url": "https://www.marketbeat.com/stock-ideas/is-johnson-and-johnson-stock-set-to-reward-long-term-holders/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-17T08:00:31-05:00", "date_et": "2025-01-17"}
{"symbol": "JNJ", "publishedDate": "2025-01-17 09:30:00", "publisher": "Accesswire", "title": "Shareholder Rights Advocates at Levi & Korsinsky Investigate Johnson & Johnson (JNJ) Regarding Possible Securities Fraud Violations", "image": "https://images.financialmodelingprep.com/news/shareholder-rights-advocates-at-levi-korsinsky-investigate-johnson-johnson-20250117.jpg", "site": "accessnewswire.com", "text": "NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/shareholder-rights-advocates-at-levi-and-korsinsky-investigate-johnson-and-johnson-jnj-regarding-possible-securities-fraud-violations-969907", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-17T09:30:00-05:00", "date_et": "2025-01-17"}
{"symbol": "JNJ", "publishedDate": "2025-01-17 10:00:00", "publisher": "Accesswire", "title": "Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-investigation-bronstein-gewirtz-grossman-llc-encourages-20250117.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/johnson-and-johnson-jnj-investigation-bronstein-gewirtz-and-grossman-llc-encourages-shareholders-to-contact-the-firm-to-learn-more-about-the-investigation-966871", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-17T10:00:00-05:00", "date_et": "2025-01-17"}
{"symbol": "JNJ", "publishedDate": "2025-01-17 11:15:00", "publisher": "Accesswire", "title": "Shareholders That Lost Money on Johnson & Johnson (JNJ) Should Contact Levi & Korsinsky About Securities Fraud Investigation - JNJ", "image": "https://images.financialmodelingprep.com/news/shareholders-that-lost-money-on-johnson-johnson-jnj-should-contact-20250117.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/shareholders-that-lost-money-on-johnson-and-johnson-jnj-should-contact-levi-and-korsinsky-about-securities-fraud-investigation--jnj-969936", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-17T11:15:00-05:00", "date_et": "2025-01-17"}
{"symbol": "JNJ", "publishedDate": "2025-01-18 06:18:00", "publisher": "The Motley Fool", "title": "3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond", "image": "https://images.financialmodelingprep.com/news/3-supersafe-dividend-stocks-to-buy-for-2025-and-20250118.jpg", "site": "fool.com", "text": "Dividend cuts can be devastating to an income-focused investor. You lose a portion of your passive income, and a dividend stock's price tends to fall significantly leading up to and after a payout reduction.", "url": "https://www.fool.com/investing/2025/01/18/3-super-safe-dividend-stocks-to-buy-for-2025-and-b/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-18T06:18:00-05:00", "date_et": "2025-01-18"}
{"symbol": "JNJ", "publishedDate": "2025-01-19 10:00:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Investors to Learn More About the Investigation", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-johnson-20250119.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-against-johnson-and-johnson-jnj-and-encourages-investors-to-learn-more-about-the-investigation-966872", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-19T10:00:00-05:00", "date_et": "2025-01-19"}
{"symbol": "JNJ", "publishedDate": "2025-01-19 10:13:00", "publisher": "Accesswire", "title": "ATTENTION JNJ SHAREHOLDERS: Investors who lost money on Johnson & Johnson are urged to contact Levi & Korsinsky about an ongoing investigation", "image": "https://images.financialmodelingprep.com/news/attention-jnj-shareholders-investors-who-lost-money-on-johnson-20250119.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESSWIRE / January 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/attention-jnj-shareholders-investors-who-lost-money-on-johnson-and-johnson-are-urged-to-contact-levi-and-korsinsky-about-an-ongoing-investigation-970617", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-19T10:13:00-05:00", "date_et": "2025-01-19"}
{"symbol": "JNJ", "publishedDate": "2025-01-20 10:00:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Stockholders to Inquire about Securities Investigation", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-encourages-johnson-johnson-jnj-stockholders-20250120.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-johnson-and-johnson-jnj-stockholders-to-inquire-about-securities-investigation-966873", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-20T10:00:00-05:00", "date_et": "2025-01-20"}
{"symbol": "JNJ", "publishedDate": "2025-01-20 10:06:25", "publisher": "Investopedia", "title": "What Analysts Think of Johnson & Johnson Stock Ahead of Earnings", "image": "https://images.financialmodelingprep.com/news/what-analysts-think-of-johnson-johnson-stock-ahead-of-20250120.jpg", "site": "investopedia.com", "text": "Johnson & Johnson (JNJ) is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from the same time last year.", "url": "https://www.investopedia.com/what-analysts-think-of-johnson-and-johnson-stock-ahead-of-earnings-8774904", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-20T10:06:25-05:00", "date_et": "2025-01-20"}
{"symbol": "JNJ", "publishedDate": "2025-01-20 11:00:00", "publisher": "Accesswire", "title": "Johnson & Johnson (JNJ) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-shareholders-may-have-been-affected-by-20250120.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/johnson-and-johnson-jnj-shareholders-may-have-been-affected-by-fraud-levi-and-korsinsky-investigates-970922", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-20T11:00:00-05:00", "date_et": "2025-01-20"}
{"symbol": "JNJ", "publishedDate": "2025-01-20 16:11:08", "publisher": "Zacks Investment Research", "title": "Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?", "image": "https://images.financialmodelingprep.com/news/should-you-buy-sell-or-hold-jj-stock-ahead-20250120.jpg", "site": "zacks.com", "text": "JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. It remains to be seen if MedTech sales improved.", "url": "https://www.zacks.com/stock/news/2400142/should-you-buy-sell-or-hold-j-j-stock-ahead-of-q4-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview-2400142", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-20T16:11:08-05:00", "date_et": "2025-01-20"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 02:30:00", "publisher": "GlobeNewsWire", "title": "NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer", "image": "https://images.financialmodelingprep.com/news/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-20250121.jpg", "site": "globenewswire.com", "text": "PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (NCT06667908). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement.", "url": "https://www.globenewswire.com/news-release/2025/01/21/3012345/0/en/NANOBIOTIX-Announces-First-Patient-Dosed-in-a-New-Randomized-Phase-2-Study-Evaluating-JNJ-1900-NBTXR3-for-Patients-With-Stage-3-Unresectable-Non-Small-Cell-Lung-Cancer.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T02:30:00-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 04:17:00", "publisher": "The Motley Fool", "title": "3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever", "image": "https://images.financialmodelingprep.com/news/3-unstoppable-dividendgrowth-stocks-yielding-more-than-3-that-20250121.jpg", "site": "fool.com", "text": "Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends to move in a positive direction regardless of what's happening to the overall economy.", "url": "https://www.fool.com/investing/2025/01/21/3-unstoppable-dividend-growth-stocks-yielding-more/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T04:17:00-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 05:34:00", "publisher": "The Motley Fool", "title": "Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?", "image": "https://images.financialmodelingprep.com/news/can-the-8-worstperforming-dow-jones-stocks-in-2024-20250121.jpg", "site": "fool.com", "text": "2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average (^DJI 0.78%) had just a 12.9% return, compared to 23.3% for the S&P 500 (^GSPC 1.00%) and 28.6% for the Nasdaq Composite.", "url": "https://www.fool.com/investing/2025/01/21/buy-2024-worst-performing-dow-jones-stocks-2025/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T05:34:00-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 06:00:00", "publisher": "The Motley Fool", "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.", "image": "https://images.financialmodelingprep.com/news/want-decades-of-passive-income-2-stocks-to-buy-now-20250121.jpg", "site": "fool.com", "text": "When most of us think of investing in stocks, we think of the potential gains -- or unfortunately, in some cases, losses -- that might follow. A particular stock will rise or fall, and we'll benefit or lose.", "url": "https://www.fool.com/investing/2025/01/21/want-decades-of-passive-income-2-stocks-to-buy-now/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T06:00:00-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 08:00:00", "publisher": "PRNewsWire", "title": "SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression", "image": "https://images.financialmodelingprep.com/news/spravato-esketamine-approved-in-the-us-as-the-first-20250121.jpg", "site": "prnewswire.com", "text": "Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours1   SPRAVATO® alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, with numerical improvements across all 10 MADRS items seen at day 28 in a post-hoc analysis2 Monotherapy data adds to well-established clinical efficacy and real-world safety profile of SPRAVATO® TITUSVILLE, N.J.", "url": "https://www.prnewswire.com/news-releases/spravato-esketamine-approved-in-the-us-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression-302355833.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T08:00:00-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 08:06:09", "publisher": "Reuters", "title": "US FDA approves J&J's ketamine-based therapy to treat depression", "image": "https://images.financialmodelingprep.com/news/us-fda-approves-jjs-ketaminebased-therapy-to-treat-depression-20250121.jpg", "site": "reuters.com", "text": "The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato, to treat adults with major depressive disorder, the company said on Tuesday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-jjs-ketamine-based-therapy-treat-depression-2025-01-21/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T08:06:09-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 08:18:41", "publisher": "CNBC", "title": "FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment", "image": "https://images.financialmodelingprep.com/news/fda-approves-johnson-johnsons-nasal-spray-for-depression-as-20250121.jpg", "site": "cnbc.com", "text": "The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.  The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient.", "url": "https://www.cnbc.com/2025/01/21/fda-approves-johnson-johnson-nasal-spray-spravato-for-depression.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T08:18:41-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 09:56:13", "publisher": "Zacks Investment Research", "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now", "image": "https://images.financialmodelingprep.com/news/why-investors-need-to-take-advantage-of-these-2-20250121.jpg", "site": "zacks.com", "text": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.", "url": "https://www.zacks.com/stock/news/2400380/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_earnings_esp-2400380", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T09:56:13-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 10:00:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-is-investigating-johnson-johnson-jnj-20250121.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-johnson-and-johnson-jnj-and-encourages-shareholders-to-connect-966874", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T10:00:00-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 10:15:00", "publisher": "Accesswire", "title": "Investors Who Lost Money on Johnson & Johnson Should Contact Levi & Korsinsky About an Ongoing Investigation - JNJ", "image": "https://images.financialmodelingprep.com/news/investors-who-lost-money-on-johnson-johnson-should-contact-20250121.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investors-who-lost-money-on-johnson-and-johnson-should-contact-levi-and-korsinsky-about-an-ongoing-investigation--jnj-971467", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T10:15:00-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 14:35:11", "publisher": "CNBC", "title": "Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?", "image": "https://images.financialmodelingprep.com/news/healthy-returns-biotech-and-pharma-ma-is-off-to-20250121.jpg", "site": "cnbc.com", "text": "Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.", "url": "https://www.cnbc.com/2025/01/21/healthy-returns-biotech-pharma-ma-picks-up-in-2025.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T14:35:11-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 15:41:13", "publisher": "Benzinga", "title": "Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-q4-earnings-loom-as-fda-approves-depression-20250121.jpg", "site": "benzinga.com", "text": "Johnson & Johnson JNJ will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and $22.44 billion in revenues as the company reports before market hours.", "url": "https://www.benzinga.com/25/01/43112811/jnjs-q4-earnings-loom-as-fda-approves-depression-drug-can-it-reverse-long-term-weakness", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T15:41:13-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-21 21:06:10", "publisher": "Zacks Investment Research", "title": "Q4 Earnings: 3 Consumer Staples Titans on Deck", "image": "https://images.financialmodelingprep.com/news/q4-earnings-3-consumer-staples-titans-on-deck-20250121.jpg", "site": "zacks.com", "text": "Among the bunch of companies expected to report in the coming days include a few consumer staples titans such as Procter & Gamble, Johnson & Johnson, and Kimberly-Clark.", "url": "https://www.zacks.com/stock/news/2400909/q4-earnings-3-consumer-staples-titans-on-deck?cid=CS-STOCKNEWSAPI-FT-stocks_in_the_news-2400909", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-21T21:06:10-05:00", "date_et": "2025-01-21"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 01:34:42", "publisher": "Benzinga", "title": "Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-earnings-are-imminent-these-most-accurate-analysts-20250122.jpg", "site": "benzinga.com", "text": "Johnson & Johnson JNJ will release earnings results for its fourth quarter, before the opening bell on Wednesday, Jan. 22, 2025.", "url": "https://www.benzinga.com/25/01/43119690/johnson-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-2", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T01:34:42-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 06:20:00", "publisher": "Business Wire", "title": "Johnson & Johnson Reports Q4 and Full-Year 2024 Results", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-reports-q4-and-fullyear-2024-results-20250122.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. \"2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “As a healthcare company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases.", "url": "https://www.businesswire.com/news/home/20250121770243/en/Johnson-Johnson-Reports-Q4-and-Full-Year-2024-Results/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T06:20:00-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 06:23:46", "publisher": "Reuters", "title": "J&J beats quarterly sales and profit estimates on cancer drug sales", "image": "https://images.financialmodelingprep.com/news/jj-beats-quarterly-sales-and-profit-estimates-on-cancer-20250122.jpg", "site": "reuters.com", "text": "Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jj-beats-quarterly-sales-profit-estimates-cancer-drug-sales-2025-01-22/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T06:23:46-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 06:51:00", "publisher": "Market Watch", "title": "J&J's stock surrenders early gains as weak sales guidance offsets earnings beat", "image": "https://images.financialmodelingprep.com/news/jjs-stock-surrenders-early-gains-as-weak-sales-guidance-20250122.jpg", "site": "marketwatch.com", "text": "Medtech and drug company's 2025 sales guidance is below consensus", "url": "https://www.marketwatch.com/story/j-js-earnings-beat-estimates-but-guidance-is-mixed-af40c571", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T06:51:00-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 07:41:45", "publisher": "CNBC Television", "title": "J&J CFO Joe Wolk: Anticipating 3% operational growth in 2025 despite 'significant' headwinds", "image": "https://images.financialmodelingprep.com/news/jj-cfo-joe-wolk-anticipating-3-operational-growth-in-20250122.jpg", "site": "youtube.com", "text": "Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, slowdown in China, health care landscape in 2025, impact of the second Trump administration, and more.", "url": "https://www.youtube.com/watch?v=XpXmhFaMc-U", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T07:41:45-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 08:31:08", "publisher": "Zacks Investment Research", "title": "Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q4-earnings-and-revenues-top-estimates-20250122.jpg", "site": "zacks.com", "text": "Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago.", "url": "https://www.zacks.com/stock/news/2401036/johnson-johnson-jnj-q4-earnings-and-revenues-top-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2401036", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T08:31:08-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 08:44:39", "publisher": "The Motley Fool", "title": "Johnson & Johnson Tops Q4 EPS Forecasts", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-tops-q4-eps-forecasts-20250122.jpg", "site": "fool.com", "text": "Pharmaceuticals and medical devices manufacturer Johnson & Johnson (JNJ 0.76%) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 billion came in just ahead of forecasts for $22.4 billion while adjusted earnings per share (EPS) of $2.04 also surpassed the $1.99 estimate.", "url": "https://www.fool.com/data-news/2025/01/22/johnson-johnson-tops-eps-forecasts/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T08:44:39-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 08:45:42", "publisher": "Investopedia", "title": "J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short", "image": "https://images.financialmodelingprep.com/news/jj-tops-q4-adjusted-earnings-estimates-but-2025-sales-20250122.jpg", "site": "investopedia.com", "text": "Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company's sales projections for the coming fiscal year fell short.", "url": "https://www.investopedia.com/johnson-and-johnson-tops-q4-adjusted-earnings-estimates-but-2025-sales-outlook-falls-short-8778310", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T08:45:42-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 09:29:13", "publisher": "Schwab Network", "title": "Trump Tariffs Take Shape, Stargate AI Project Ramps Up, JNJ & PG Beat", "image": "https://images.financialmodelingprep.com/news/trump-tariffs-take-shape-stargate-ai-project-ramps-up-20250122.jpg", "site": "youtube.com", "text": "Kevin Green joins Morning Movers to look at how President Trump's tariffs plan could impact several areas of the market, specifically currencies and copper. Then, the focus shifts to Trump's ambitious A.I.", "url": "https://www.youtube.com/watch?v=HfhtOyGDyX4", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T09:29:13-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 10:00:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities Investigation", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-encourages-johnson-johnson-jnj-shareholders-20250122.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-johnson-and-johnson-jnj-shareholders-to-inquire-about-securities-investigation-966875", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T10:00:00-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 10:21:05", "publisher": "Schaeffers Research", "title": "Dow Earnings: Procter & Gamble, Johnson & Johnson", "image": "https://images.financialmodelingprep.com/news/dow-earnings-procter-gamble-johnson-johnson-20250122.jpg", "site": "schaeffersresearch.com", "text": "Blue-chip earnings reports continue to roll in , with results from Procter & Gamble Co (NYSE:PG) and Johnson & Johnson (NYSE:JNJ) on tap.", "url": "https://www.schaeffersresearch.com/content/news/2025/01/22/dow-earnings-procter-gamble-johnson-johnson", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T10:21:05-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 10:30:00", "publisher": "Accesswire", "title": "Johnson & Johnson Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - JNJ", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-investigated-by-shareholder-rights-advocates-investors-should-20250122.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/johnson-and-johnson-investigated-by-shareholder-rights-advocates--investors-should-contact-levi-and-korsinsky-regarding-potential-securities-law-violations--jnj-972148", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T10:30:00-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 10:31:32", "publisher": "Zacks Investment Research", "title": "Compared to Estimates, Johnson & Johnson (JNJ) Q4 Earnings: A Look at Key Metrics", "image": "https://images.financialmodelingprep.com/news/compared-to-estimates-johnson-johnson-jnj-q4-earnings-a-20250122.jpg", "site": "zacks.com", "text": "The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.", "url": "https://www.zacks.com/stock/news/2401237/compared-to-estimates-johnson-johnson-jnj-q4-earnings-a-look-at-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2401237", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T10:31:32-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 10:31:45", "publisher": "Proactive Investors", "title": "Johnson & Johnson slides as soft sales guidance casts shadow", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-slides-as-soft-sales-guidance-casts-shadow-20250122.jpg", "site": "proactiveinvestors.com", "text": "Johnson & Johnson shares faced pressure on Wednesday as soft sales guidance for the coming year cast a shadow over expectation-beating fourth-quarter profit. Adjusted net earnings of US$4.95 billion were down 11.1% year on year in the fourth quarter, J&J reported, but ahead of consensus expectations for US$4.88 billion.", "url": "https://www.proactiveinvestors.com/companies/news/1064860", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T10:31:45-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 11:41:09", "publisher": "Zacks Investment Research", "title": "Leading Indicators Data in Focus", "image": "https://images.financialmodelingprep.com/news/leading-indicators-data-in-focus-20250122.jpg", "site": "zacks.com", "text": "Ahead of today's regular stock market trading session, pre-market futures are picking up where they left off Tuesday afternoon: higher. Continued optimism for a pro-growth Trump administration are sending major indexes to loftier reaches: the Dow is currently +145 points (+0.33%), the S&P 500 is +34 (+0.56%) and the Nasdaq +219 points (+1.01%).", "url": "https://www.zacks.com/stock/news/2401421/leading-indicators-data-in-focus?cid=CS-STOCKNEWSAPI-FT-economic_highlights-2401421", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T11:41:09-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 11:51:14", "publisher": "Zacks Investment Research", "title": "J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance", "image": "https://images.financialmodelingprep.com/news/jjs-q4-earnings-beat-stock-down-on-tepid-2025-20250122.jpg", "site": "zacks.com", "text": "JNJ beats estimates for fourth-quarter earnings and sales. Its sales guidance for 2025 falls short of expectations.", "url": "https://www.zacks.com/stock/news/2401430/j-j-s-q4-earnings-beat-stock-down-on-tepid-2025-sales-guidance?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2401430", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T11:51:14-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 12:09:31", "publisher": "Seeking Alpha", "title": "Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q4-2024-earnings-call-transcript-20250122.jpg", "site": "seekingalpha.com", "text": "Johnson & Johnson (NYSE:JNJ ) Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk - Executive Vice President, Chief Financial Officer Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Conference Call Participants Terence Flynn - Morgan Stanley Joshua Jennings - TD Cowen Alexandria Hammond - Wolfe Research Tim Anderson - Bank of America Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan David Roman - Goldman Sachs Operator Good morning and welcome to Johnson & Johnson's Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.", "url": "https://seekingalpha.com/article/4751206-johnson-and-johnson-jnj-q4-2024-earnings-call-transcript", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T12:09:31-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 12:15:18", "publisher": "Zacks Investment Research", "title": "J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use", "image": "https://images.financialmodelingprep.com/news/jjs-depression-drug-spravato-gets-fda-nod-for-monotherapy-20250122.jpg", "site": "zacks.com", "text": "The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.", "url": "https://www.zacks.com/stock/news/2401458/j-j-s-depression-drug-spravato-gets-fda-nod-for-monotherapy-use?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2401458", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T12:15:18-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 12:24:36", "publisher": "Seeking Alpha", "title": "Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-dips-on-q4-earnings-heres-what-the-20250122.jpg", "site": "seekingalpha.com", "text": "Johnson & Johnson's Q4 2024 earnings missed EPS expectations but broadly met revenue targets; full-year 2024 showed 4.3% sales growth and $5.79 EPS. Despite short-term challenges, including Stelara's patent loss, JNJ's long-term growth strategy focuses on high-growth markets and promising pipeline products. JNJ's MedTech division showed strong performance, with significant investments in cardiovascular and surgical robotics expected to drive future growth.", "url": "https://seekingalpha.com/article/4751193-johnson-and-johnson-dips-on-q4-earnings-heres-what-the-market-isnt-seeing", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T12:24:36-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 15:00:00", "publisher": "Accesswire", "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ", "image": "https://images.financialmodelingprep.com/news/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson-20250122.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson(\"J&J\" or the \"Company\") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson-and-johnson--jnj-972373", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T15:00:00-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 15:28:18", "publisher": "CNBC Television", "title": "3-Stock Lunch: Netflix, Johnson & Johnson, Travelers", "image": "https://images.financialmodelingprep.com/news/3stock-lunch-netflix-johnson-johnson-travelers-20250122.jpg", "site": "youtube.com", "text": "Sarat Sethi, DCLA managing partner, joins 'Power Lunch' to discuss stock plays for three stocks.", "url": "https://www.youtube.com/watch?v=0BADq7Lkv98", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T15:28:18-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 15:30:00", "publisher": "Accesswire", "title": "ATTENTION Johnson & Johnson Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights", "image": "https://images.financialmodelingprep.com/news/attention-johnson-johnson-investors-you-may-have-been-affected-20250122.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/attention-johnson-and-johnson-investors-you-may-have-been-affected-by-fraud--contact-levi-and-korsinsky-to-discuss-your-rights-972387", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T15:30:00-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 16:51:02", "publisher": "Fast Company", "title": "Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-ketaminederived-nasal-spray-gets-fda-approval-for-20250122.jpg", "site": "fastcompany.com", "text": "On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson's nasal spray, Spravato (esketamine), to treat major depressive disorder.", "url": "https://www.fastcompany.com/91265313/jnj-stock-dips-johnson-johnson-ketamine-depression-treatment-nasal-spray-fda-approval", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T16:51:02-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 19:05:28", "publisher": "Zacks Investment Research", "title": "Earnings Picture Remains Strong: A Closer Look", "image": "https://images.financialmodelingprep.com/news/earnings-picture-remains-strong-a-closer-look-20250122.jpg", "site": "zacks.com", "text": "The picture emerging from the 2024 Q4 earnings season is one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the coming quarters.", "url": "https://www.zacks.com/commentary/2401637/earnings-picture-remains-strong-a-closer-look?cid=CS-STOCKNEWSAPI-FT-earnings_trends-2401637", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T19:05:28-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-22 19:05:29", "publisher": "Zacks Investment Research", "title": "Earnings Picture Remains Strong: A Closer Look", "image": "https://images.financialmodelingprep.com/news/earnings-picture-remains-strong-a-closer-look-20250122.jpg", "site": "zacks.com", "text": "The picture emerging from the 2024 Q4 earnings season is one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the coming quarters.", "url": "https://www.zacks.com/commentary/2401685/earnings-picture-remains-strong-a-closer-look?cid=CS-STOCKNEWSAPI-FT-earnings_outlook-2401685", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-22T19:05:29-05:00", "date_et": "2025-01-22"}
{"symbol": "JNJ", "publishedDate": "2025-01-23 05:08:00", "publisher": "The Motley Fool", "title": "This Is 1 of the Healthiest High-Yielding Dividend Stocks You'll Find", "image": "https://images.financialmodelingprep.com/news/this-is-1-of-the-healthiest-highyielding-dividend-stocks-20250123.jpg", "site": "fool.com", "text": "Johnson & Johnson (JNJ -1.94%) is an elite dividend stock. The healthcare giant has increased its dividend payment for 62 years in a row.", "url": "https://www.fool.com/investing/2025/01/23/this-is-1-of-the-healthiest-high-yielding-dividend/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-23T05:08:00-05:00", "date_et": "2025-01-23"}
{"symbol": "JNJ", "publishedDate": "2025-01-23 05:35:00", "publisher": "PRNewsWire", "title": "Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology", "image": "https://images.financialmodelingprep.com/news/findings-from-pivotal-nipocalimab-phase-3-study-in-a-20250123.jpg", "site": "prnewswire.com", "text": "The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a sustained reduction in autoantibody levels, one of the underlying causes of gMG, by up to 75% over a period of 24 weeks The investigational therapy was recently granted U.S. FDA Priority Review for the treatment of gMG SPRING HOUSE, Pa. , Jan. 23, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad population of antibody positive (anti-AChR+, anti-MuSK+, anti-LRP4+) adults with generalized myasthenia gravis (gMG).1 The Vivacity-MG3 study met its primary endpoint demonstrating statistically significant and clinically meaningful improvement over 24 weeks in the MG-ADLa score.1 Nipocalimab had a tolerable safety profile, with adverse events leading to discontinuation rates similar to placebo (5.1% with nipocalimab vs.", "url": "https://www.prnewswire.com/news-releases/findings-from-pivotal-nipocalimab-phase-3-study-in-a-broad-antibody-positive-population-of-people-living-with-generalized-myasthenia-gravis-gmg-published-in-the-lancet-neurology-302358507.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-23T05:35:00-05:00", "date_et": "2025-01-23"}
{"symbol": "JNJ", "publishedDate": "2025-01-23 06:01:00", "publisher": "Accesswire", "title": "Lost Money on Johnson & Johnson(JNJ)? Contact Levi & Korsinsky Regarding an Ongoing Investigation", "image": "https://images.financialmodelingprep.com/news/lost-money-on-johnson-johnsonjnj-contact-levi-korsinsky-regarding-20250123.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/lost-money-on-johnson-and-johnsonjnj-contact-levi-and-korsinsky-regarding-an-ongoing-investigation-972647", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-23T06:01:00-05:00", "date_et": "2025-01-23"}
{"symbol": "JNJ", "publishedDate": "2025-01-23 10:00:00", "publisher": "Accesswire", "title": "Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-investigation-bronstein-gewirtz-grossman-llc-encourages-20250123.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/johnson-and-johnson-jnj-investigation-bronstein-gewirtz-and-grossman-llc-encourages-investors-to-contact-the-firm-to-learn-more-about-the-investigation-966876", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-23T10:00:00-05:00", "date_et": "2025-01-23"}
{"symbol": "JNJ", "publishedDate": "2025-01-23 10:30:00", "publisher": "Accesswire", "title": "Johnson & Johnson Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - JNJ", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-investigation-ongoing-contact-levi-korsinsky-about-potential-20250123.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/johnson-and-johnson-investigation-ongoing-contact-levi-and-korsinsky-about-potential-securities-fraud-allegations--jnj-972735", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-23T10:30:00-05:00", "date_et": "2025-01-23"}
{"symbol": "JNJ", "publishedDate": "2025-01-23 12:45:23", "publisher": "Zacks Investment Research", "title": "Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now", "image": "https://images.financialmodelingprep.com/news/why-johnson-johnson-jnj-is-a-great-dividend-stock-20250123.jpg", "site": "zacks.com", "text": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?", "url": "https://www.zacks.com/stock/news/2402370/why-johnson-johnson-jnj-is-a-great-dividend-stock-right-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_5-2402370", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-23T12:45:23-05:00", "date_et": "2025-01-23"}
{"symbol": "JNJ", "publishedDate": "2025-01-23 15:02:29", "publisher": "Benzinga", "title": "Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst", "image": "https://images.financialmodelingprep.com/news/johnson-johnsons-medtech-momentum-expected-to-rebound-in-2025-20250123.jpg", "site": "benzinga.com", "text": "On Wednesday, Johnson & Johnson JNJ reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01.", "url": "https://www.benzinga.com/general/biotech/25/01/43174150/johnson-johnsons-medtech-momentum-expected-to-rebound-in-2025-despite-current-hurdles-analyst", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-23T15:02:29-05:00", "date_et": "2025-01-23"}
{"symbol": "JNJ", "publishedDate": "2025-01-24 04:51:00", "publisher": "The Motley Fool", "title": "5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025", "image": "https://images.financialmodelingprep.com/news/5-of-the-safest-highyield-dividend-stocks-you-can-20250124.jpg", "site": "fool.com", "text": "With thousands of publicly traded companies and exchange-traded funds (ETFs) to choose from, Wall Street offers countless ways for investors to grow their wealth. Though there's no one-size-fits-all blueprint to make bank, buying and holding high-quality dividend stocks has a favorable track record of delivering for investors.", "url": "https://www.fool.com/investing/2025/01/24/5-safest-high-yield-dividend-stocks-buy-for-2025/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-24T04:51:00-05:00", "date_et": "2025-01-24"}
{"symbol": "JNJ", "publishedDate": "2025-01-24 06:30:35", "publisher": "Forbes", "title": "What's Next For JNJ Stock After An Upbeat Q4?", "image": "https://images.financialmodelingprep.com/news/whats-next-for-jnj-stock-after-an-upbeat-q4-20250124.jpg", "site": "forbes.com", "text": "Johnson & Johnson (NYSE: JNJ) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates of $22.4 billion and $2.02, respectively.", "url": "https://www.forbes.com/sites/greatspeculations/2025/01/24/johnson--johnson-stock-riding-the-q4-wave-into-2025/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-24T06:30:35-05:00", "date_et": "2025-01-24"}
{"symbol": "JNJ", "publishedDate": "2025-01-24 10:00:00", "publisher": "Accesswire", "title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Shareholders to Learn More About the Investigation", "image": "https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-johnson-20250124.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (\"J&J\" or \"the Company\") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-aga-966877", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-24T10:00:00-05:00", "date_et": "2025-01-24"}
{"symbol": "JNJ", "publishedDate": "2025-01-24 10:30:00", "publisher": "Accesswire", "title": "Johnson & Johnson Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - JNJ", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-investigated-by-shareholder-rights-advocates-investors-should-20250124.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/johnson-and-johnson-investigated-by-shareholder-rights-advocates--973405", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-24T10:30:00-05:00", "date_et": "2025-01-24"}
{"symbol": "JNJ", "publishedDate": "2025-01-24 12:00:00", "publisher": "Accesswire", "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ", "image": "https://images.financialmodelingprep.com/news/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-20250124.jpg", "site": "accessnewswire.com", "text": "NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson(\"J&J\" or the \"Company\") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behal-973022", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-24T12:00:00-05:00", "date_et": "2025-01-24"}
{"symbol": "JNJ", "publishedDate": "2025-01-24 13:00:00", "publisher": "Accesswire", "title": "JNJ ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Johnson & Johnson", "image": "https://images.financialmodelingprep.com/news/jnj-alert-levi-korsinsky-reminds-investors-of-an-investigation-20250124.jpg", "site": "accessnewswire.com", "text": "NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (\"Johnson & Johnson\") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that \"on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/jnj-alert-levi-and-korsinsky-reminds-investors-of-an-investigatio-973556", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-24T13:00:00-05:00", "date_et": "2025-01-24"}
{"symbol": "JNJ", "publishedDate": "2025-01-25 06:05:25", "publisher": "Invezz", "title": "Best 5 dividend aristocrat stocks to buy and hold", "image": "https://images.financialmodelingprep.com/news/best-5-dividend-aristocrat-stocks-to-buy-and-hold-20250125.jpg", "site": "invezz.com", "text": "Dividend aristocrats, or companies that have paid and raised dividends for at least 25 years are some of the best value stocks to buy and hold. Many of them have solid balance sheets and a long record of doing well for their share holders.", "url": "https://invezz.com/news/2025/01/25/best-5-dividend-aristocrat-stocks-to-buy-and-hold/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-25T06:05:25-05:00", "date_et": "2025-01-25"}
{"symbol": "JNJ", "publishedDate": "2025-01-25 06:17:00", "publisher": "The Motley Fool", "title": "These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024", "image": "https://images.financialmodelingprep.com/news/these-were-the-5-worstperforming-stocks-in-the-dow-20250125.jpg", "site": "fool.com", "text": "The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening in the economy and the markets.", "url": "https://www.fool.com/investing/2025/01/25/these-were-the-5-worst-performing-stocks-in-the-do/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-25T06:17:00-05:00", "date_et": "2025-01-25"}
{"symbol": "JNJ", "publishedDate": "2025-01-25 07:38:05", "publisher": "MarketBeat", "title": "Why Traders Are Buying the Dip on Johnson & Johnson Stock", "image": "https://images.financialmodelingprep.com/news/why-traders-are-buying-the-dip-on-johnson-johnson-20250125.jpg", "site": "marketbeat.com", "text": "It is no secret that the defensive names in the stock market today, the ones not known for their hot price action or wild return potential, have been the lackluster segment of the financial markets lately. This is because the center of attention has been taken by the technology sector and some of the darling names in that space for all of 2023 and 2024.", "url": "https://www.marketbeat.com/stock-ideas/why-traders-are-buying-the-dip-on-johnson-and-johnson-stock/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-25T07:38:05-05:00", "date_et": "2025-01-25"}
{"symbol": "JNJ", "publishedDate": "2025-01-26 12:00:00", "publisher": "Accesswire", "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ", "image": "https://images.financialmodelingprep.com/news/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-20250126.jpg", "site": "accessnewswire.com", "text": "NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson(\"J&J\" or the \"Company\") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behal-973626", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-26T12:00:00-05:00", "date_et": "2025-01-26"}
{"symbol": "JNJ", "publishedDate": "2025-01-27 10:06:22", "publisher": "Zacks Investment Research", "title": "Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock", "image": "https://images.financialmodelingprep.com/news/here-is-what-to-know-beyond-why-johnson-johnson-20250127.jpg", "site": "zacks.com", "text": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "url": "https://www.zacks.com/stock/news/2403674/here-is-what-to-know-beyond-why-johnson-johnson-jnj-is-a-trending-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2403674", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-27T10:06:22-05:00", "date_et": "2025-01-27"}
{"symbol": "JNJ", "publishedDate": "2025-01-27 10:34:46", "publisher": "24/7 Wall Street", "title": "The Stock Market Is Overbought and Insiders Are Selling – Grab These 5 High-Yield Blue Chips Now", "image": "https://images.financialmodelingprep.com/news/the-stock-market-is-overbought-and-insiders-are-selling-20250127.jpg", "site": "247wallst.com", "text": "Investors love dividend stocks, especially the blue-chip variety, because they offer a significant income stream and have massive total return potential.", "url": "https://247wallst.com/investing/2025/01/27/the-stock-market-is-overbought-and-insiders-are-selling-grab-these-5-high-yield-blue-chips-now/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-27T10:34:46-05:00", "date_et": "2025-01-27"}
{"symbol": "JNJ", "publishedDate": "2025-01-27 16:15:21", "publisher": "Zacks Investment Research", "title": "How to Play J&J Stock After Q4 Beat & Soft 2025 Sales Guidance", "image": "https://images.financialmodelingprep.com/news/how-to-play-jj-stock-after-q4-beat-soft-20250127.jpg", "site": "zacks.com", "text": "Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.", "url": "https://www.zacks.com/stock/news/2404132/how-to-play-j-j-stock-after-q4-beat-soft-2025-sales-guidance?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2404132", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-27T16:15:21-05:00", "date_et": "2025-01-27"}
{"symbol": "JNJ", "publishedDate": "2025-01-27 16:22:59", "publisher": "Proactive Investors", "title": "Spravato sales surged highlights commercial viability of psychedelics, analysts believe", "image": "https://images.financialmodelingprep.com/news/spravato-sales-surged-highlights-commercial-viability-of-psychedelics-analysts-20250127.jpg", "site": "proactiveinvestors.com", "text": "The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferies believe. Fourth quarter Spravato sales grew by 5% quarter-over-quarter to $297 million driven by increased physician and patient demand.", "url": "https://www.proactiveinvestors.com/companies/news/1065123", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-27T16:22:59-05:00", "date_et": "2025-01-27"}
{"symbol": "JNJ", "publishedDate": "2025-01-28 07:45:05", "publisher": "MarketBeat", "title": "3 Stocks Upgraded by Bank of America – Here's Why They're Bullish", "image": "https://images.financialmodelingprep.com/news/3-stocks-upgraded-by-bank-of-america-heres-why-20250128.jpg", "site": "marketbeat.com", "text": "The new trading year is getting started, and investors might be looking to make this one either as strong as 2024 was or even stronger yet. To do this, it is always preferred to start on a strong note, meaning that the first quarter of the year has to bring about a net outperformance to give portfolios enough momentum and room to pursue some of the more aggressive growth projects later in the year.", "url": "https://www.marketbeat.com/stock-ideas/3-stocks-upgraded-by-bank-of-america-heres-why-theyre-bullish/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-28T07:45:05-05:00", "date_et": "2025-01-28"}
{"symbol": "JNJ", "publishedDate": "2025-01-28 10:41:43", "publisher": "Zacks Investment Research", "title": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock", "image": "https://images.financialmodelingprep.com/news/heres-why-johnson-johnson-jnj-is-a-strong-value-20250128.jpg", "site": "zacks.com", "text": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.", "url": "https://www.zacks.com/stock/news/2404612/here-s-why-johnson-johnson-jnj-is-a-strong-value-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_value_score-2404612", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-28T10:41:43-05:00", "date_et": "2025-01-28"}
{"symbol": "JNJ", "publishedDate": "2025-01-28 10:45:48", "publisher": "24/7 Wall Street", "title": "Two Sigma Sells These Stocks Amidst Departure of Billionaire Founders", "image": "https://images.financialmodelingprep.com/news/two-sigma-sells-these-stocks-amidst-departure-of-billionaire-20250128.jpg", "site": "247wallst.com", "text": "Two Sigma Investments founders John Overdeck and David Siegel are worth an estimated $14 billion.", "url": "https://247wallst.com/investing/2025/01/28/two-sigma-sells-these-stocks-amidst-departure-of-billionaire-founders/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-28T10:45:48-05:00", "date_et": "2025-01-28"}
{"symbol": "JNJ", "publishedDate": "2025-01-28 12:50:00", "publisher": "PRNewsWire", "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ", "image": "https://images.financialmodelingprep.com/news/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson-20250128.jpg", "site": "prnewswire.com", "text": "NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (\"J&J\" or the \"Company\") (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson--johnson---jnj-302361783.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-28T12:50:00-05:00", "date_et": "2025-01-28"}
{"symbol": "JNJ", "publishedDate": "2025-01-30 12:00:00", "publisher": "Accesswire", "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ", "image": "https://images.financialmodelingprep.com/news/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson-20250130.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson(\"J&J\" or the \"Company\") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behal-975287", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-30T12:00:00-05:00", "date_et": "2025-01-30"}
{"symbol": "JNJ", "publishedDate": "2025-01-30 17:03:15", "publisher": "Seeking Alpha", "title": "Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)", "image": "https://images.financialmodelingprep.com/news/why-johnson-johnsons-strong-buy-rating-is-justified-rating-20250130.jpg", "site": "seekingalpha.com", "text": "On January 22, Johnson & Johnson released financial results for the fourth quarter of 2024, which beat my expectations again. So, sales of its oncology franchise reached $5.5 billion, an increase of 19% compared to the fourth quarter of 2023. Moreover, Johnson & Johnson expects its operational sales to grow by 2% to 3% in 2025, while its adjusted diluted EPS will be between $10.50 and $10.70, implying single-digit percentage growth.", "url": "https://seekingalpha.com/article/4753589-why-johnson-and-johnsons-strong-buy-rating-is-justified", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-30T17:03:15-05:00", "date_et": "2025-01-30"}
{"symbol": "JNJ", "publishedDate": "2025-01-31 17:12:45", "publisher": "Reuters", "title": "US government could seek over $1 billion from J&J for cancer treatment costs", "image": "https://images.financialmodelingprep.com/news/us-government-could-seek-over-1-billion-from-jj-20250131.jpg", "site": "reuters.com", "text": "The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal health agencies' payments of medical costs for patients who allege that the company's baby powder and other talc products caused them to develop cancer, a government attorney said Friday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-government-could-seek-over-1-billion-jj-cancer-treatment-costs-2025-01-31/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-01-31T17:12:45-05:00", "date_et": "2025-01-31"}
{"symbol": "JNJ", "publishedDate": "2025-02-01 06:14:00", "publisher": "The Motley Fool", "title": "Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?", "image": "https://images.financialmodelingprep.com/news/did-johnson-johnson-just-give-investors-23-billion-reasons-20250201.jpg", "site": "fool.com", "text": "Johnson & Johnson (JNJ -0.47%) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year.", "url": "https://www.fool.com/investing/2025/02/01/did-johnson-johnson-just-give-investors-23-billion/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-01T06:14:00-05:00", "date_et": "2025-02-01"}
{"symbol": "JNJ", "publishedDate": "2025-02-01 07:30:00", "publisher": "The Motley Fool", "title": "Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-announces-a-major-acquisition-can-it-turn-20250201.jpg", "site": "fool.com", "text": "Johnson & Johnson (JNJ -0.47%) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however, is growth.", "url": "https://www.fool.com/investing/2025/02/01/johnson-johnson-announces-a-major-acquisition-can/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-01T07:30:00-05:00", "date_et": "2025-02-01"}
{"symbol": "JNJ", "publishedDate": "2025-02-01 10:00:00", "publisher": "Accesswire", "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ", "image": "https://images.financialmodelingprep.com/news/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson-20250201.jpg", "site": "accessnewswire.com", "text": "NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson(\"J&J\" or the \"Company\") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behal-977705", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-01T10:00:00-05:00", "date_et": "2025-02-01"}
{"symbol": "JNJ", "publishedDate": "2025-02-02 12:21:00", "publisher": "The Motley Fool", "title": "Is Johnson & Johnson Stock a Buy?", "image": "https://images.financialmodelingprep.com/news/is-johnson-johnson-stock-a-buy-20250202.jpg", "site": "fool.com", "text": "Johnson & Johnson (JNJ -0.47%) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy.", "url": "https://www.fool.com/investing/2025/02/02/is-johnson-johnson-stock-a-buy/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-02T12:21:00-05:00", "date_et": "2025-02-02"}
{"symbol": "JNJ", "publishedDate": "2025-02-03 08:51:00", "publisher": "Seeking Alpha", "title": "You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth", "image": "https://images.financialmodelingprep.com/news/you-deserve-reliable-income-2-undervalued-dividends-for-longterm-20250203.jpg", "site": "seekingalpha.com", "text": "A buy-and-hold strategy is ideal for investors seeking durable companies with strong dividends and attractive valuations, avoiding tax inefficiencies from frequent trading. UPS offers a 5.7% dividend yield, trading at a forward P/E of 13.5, with potential for profitability expansion despite near-term Amazon volume reductions. Johnson & Johnson, with a 3.3% dividend yield and a forward P/E of 14.4, carries a robust pipeline and 62 years of consecutive dividend growth.", "url": "https://seekingalpha.com/article/4754265-you-deserve-reliable-income-2-undervalued-dividends-for-long-term-growth", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-03T08:51:00-05:00", "date_et": "2025-02-03"}
{"symbol": "JNJ", "publishedDate": "2025-02-03 16:30:00", "publisher": "Business Wire", "title": "Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-45th-annual-td-20250203.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.", "url": "https://www.businesswire.com/news/home/20250203221873/en/Johnson-Johnson-to-Participate-in-the-45th-Annual-TD-Cowen-Healthcare-Conference/", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-03T16:30:00-05:00", "date_et": "2025-02-03"}
{"symbol": "JNJ", "publishedDate": "2025-02-04 12:10:41", "publisher": "Zacks Investment Research", "title": "CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi", "image": "https://images.financialmodelingprep.com/news/chmp-gives-nod-to-expanded-use-of-jjs-rybrevant-20250204.jpg", "site": "zacks.com", "text": "The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.", "url": "https://www.zacks.com/stock/news/2409380/chmp-gives-nod-to-expanded-use-of-j-j-s-rybrevant-azn-s-imfinzi?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2409380", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-04T12:10:41-05:00", "date_et": "2025-02-04"}
{"symbol": "JNJ", "publishedDate": "2025-02-04 15:55:00", "publisher": "PRNewsWire", "title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ", "image": "https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson-20250204.jpg", "site": "prnewswire.com", "text": "NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson. (\"J&J\" or the \"Company\") (NYSE: JNJ).", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson--johnson---jnj-302367989.html", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-04T15:55:00-05:00", "date_et": "2025-02-04"}
{"symbol": "JNJ", "publishedDate": "2025-02-05 07:58:38", "publisher": "CNBC Television", "title": "DCLA's Sarat Sethi on his top stock picks: JNJ, WDAY, TMO", "image": "https://images.financialmodelingprep.com/news/dclas-sarat-sethi-on-his-top-stock-picks-jnj-20250205.jpg", "site": "youtube.com", "text": "Sarat Sethi, DCLA managing partner, joins 'Squawk Box' to discuss the latest market trends, his top stock picks, and more.", "url": "https://www.youtube.com/watch?v=AzxeJxp0gBk", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-05T07:58:38-05:00", "date_et": "2025-02-05"}
{"symbol": "JNJ", "publishedDate": "2025-02-05 14:00:00", "publisher": "Seeking Alpha", "title": "My Top 5 Dividend-Paying Buy-And-Hold Stocks For 2025", "image": "https://images.financialmodelingprep.com/news/my-top-5-dividendpaying-buyandhold-stocks-for-2025-20250205.jpg", "site": "seekingalpha.com", "text": "With both The Dividend Income Accelerator Portfolio and my personal investment portfolio I am following a buy-and-hold approach. While my private portfolio focuses on dividend growth, The Dividend Income Accelerator Portfolio balances both dividend income and dividend growth. Investing in companies with strong dividend growth potential allows you to not only benefit from annually increasing dividend payments, but also from capital appreciation.", "url": "https://seekingalpha.com/article/4754469-my-top-5-dividend-paying-buy-and-hold-stocks-for-2025", "ticker": "JNJ", "event_date": "2025-01-22", "window_start": "2025-01-08", "window_end": "2025-02-05", "publishedDateET": "2025-02-05T14:00:00-05:00", "date_et": "2025-02-05"}
